In our May 2022 Mid-Month Update for Inside Arbitrage Premium and Plus members, we discussed the acquisition of Biohaven Pharmaceuticals by Pfizer (PFE) and wrote
Read More
Summary: Both the Biohaven deal discussed in our May 2022 Mid-Month update and the Bluerock Residential Growth REIT deal discussed in our January 2022 Special
Read More
We discussed the macro economic environment in our Buyback Wednesdays post this Wednesday and the idea I want to discuss for this mid-month update will likely
Read More
The last two months have been a relief for most investors with exposure on the long side with a significant rally off the June 16th
Read More
When we started the month of July, there was speculation about the Fed raising interest rates anywhere from 50 basis points to 75 basis points
Read More
After an intra-day dip into bear market territory in May, the S&P 500 finally entered a bear market earlier this month. We saw some moderation
Read More
Current market conditions have impacted several previously uncorrelated assets that dropped in unison over the last couple of weeks and we have also seen merger
Read More
Considering most of the Inside Arbitrage Model Portfolio companies are yet to report quarterly results, we decided to focus on a new opportunity with recent
Read More
It is amazing how quickly things can unravel and conditions have gotten worse on multiple fronts during the last two weeks. In addition to the
Read More
The big Consumer Price Index (CPI) number reported last week appears to have put to rest the idea that the increase in inflation we were
Read More
The sector and style rotation we started seeing towards the end of 2021 picked up steam in the first two weeks of January. In our
Read More
This is the third post in a new series that we publish mid-month for InsideArbitrage Premium and InsideArbitrage Plus subscribers. These posts will contain updates
Read More